Morgan Stanley Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $13
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.
Morgan Stanley analyst Sean Laaman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $18 to $13.